

Citation for published version:

Thomas, KH, Davies, NM, Taylor, AE, Taylor, GMJ, Gunnell, D, Martin, RM & Douglas, I 2021, 'Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case-crossover study', *Addiction*, vol. 116, no. 6, pp. 1532-1545. <https://doi.org/10.1111/add.15338>

DOI:

[10.1111/add.15338](https://doi.org/10.1111/add.15338)

Publication date:

2021

Document Version

Peer reviewed version

[Link to publication](#)

This is the peer reviewed version of the following article: Thomas, K. H., Davies, N. M., Taylor, A. E., Taylor, G. M. J., Gunnell, D., Martin, R. M., and Douglas, I. (2020) Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a casecrossover study. *Addiction*, , which has been published in final form at <https://doi.org/10.1111/add.15338>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

ADDICTION

SSA SOCIETY FOR THE
STUDY OF
ADDICTION

**Risk of neuropsychiatric and cardiovascular adverse events
following treatment with varenicline and nicotine
replacement therapy in the UK Clinical Practice Research
Datalink: a case-crossover study**

Journal:	<i>Addiction</i>
Manuscript ID	ADD-19-0986.R2
Manuscript Type:	Research Report
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Thomas, Kyla; University of Bristol, Bristol Medical School Davies, Neil; University of Bristol, Bristol Medical School; Medical Research Council Integrative Epidemiology Unit, University of Bristol; K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology Taylor, Amy; University of Bristol, Bristol Medical School; University Hospitals Bristol NHS Foundation Trust and University of Bristol, National Institute for Health Research Bristol Biomedical Research Centre Taylor, Gemma; University of Bath, Addiction and Mental Health Group (AIM), Department of Psychology Gunnell, David; University of Bristol, Bristol Medical School; University Hospitals Bristol NHS Foundation Trust and University of Bristol, National Institute for Health Research Bristol Biomedical Research Centre Martin, Richard; University of Bristol, Bristol Medical School; University of Bristol, Medical Research Council Integrative Epidemiology Unit Douglas, Ian; London School of Hygiene and Tropical Medicine, Department of Non-communicable Disease Epidemiology</p>
SUBSTANCE:	tobacco
METHOD:	cohort/longitudinal studies
FIELD OF STUDY:	epidemiology
Keywords:	varenicline, nicotine replacement therapy, adverse events, observational study, cardiovascular, neuropsychiatric

Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case-crossover study

Authors:

Kyla H Thomas ¹, Neil M Davies ^{1,2,3}, Amy E Taylor ^{1,4}, Gemma M J Taylor ⁵, David Gunnell ^{1,4}, Richard M Martin ^{1,2,4}, Ian Douglas ⁶

1. Bristol Medical School, Population Health Sciences, Canynge Hall, University of Bristol, Bristol, Bristol, BS8 2PS, United Kingdom.

2. Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, United Kingdom.

3. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Norway.

4. National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, United Kingdom.

5. Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, BA2 7AY, United Kingdom.

6. Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, LSHTM, London, WC1E 7HT, United Kingdom.

Corresponding Author: Kyla Thomas, Bristol Medical School, Population Health Sciences, Canynge Hall, Bristol, BS8 2PS, kyla.thomas@bristol.ac.uk

Running Head: Safety of varenicline and NRT

Words: 5000 (excluding abstract, references, tables, figures). **Tables:** 2 **Figures:** 3

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: KHT received funding for the project from the Academy of Medical Sciences Starter Grant for Clinical Lecturers Scheme (supported by the Wellcome Trust, British Heart Foundation, Medical Research Council, Versus Arthritis, Prostate Cancer UK and the Royal College of Physicians). AT has received a Global Research Award for Nicotine Dependence (GRAND), an independently reviewed, competitive grants programme supported by Pfizer, to the University of Bristol. IJD is supported by an unrestricted grant from GlaxoSmithKline and holds shares in GlaxoSmithKline.

Keywords: varenicline, nicotine replacement therapy, adverse events, observational study, cardiovascular, neuropsychiatric

44 ABSTRACT

45 **Background:** Varenicline and nicotine replacement therapy (NRT) are the most
46 commonly used medications to quit smoking. Given their widespread use, monitoring
47 adverse risks remains important.

48 **Aims:** To estimate the neuropsychiatric and cardiovascular risks associated with
49 varenicline and NRT as used in routine UK care.

50 **Design:** Case crossover study.

51 **Setting:** UK based electronic primary care records in the Clinical Practice Research
52 Datalink from 2006 to 2015 linked to hospital and mortality datasets.

53 **Participants:** Adult smokers observed in periods when exposed and not exposed to
54 either varenicline or NRT.

55 **Measurements:** Main outcomes include suicide, self-harm, myocardial infarction
56 (MI), all-cause and cause-specific death (MI, chronic obstructive pulmonary disease
57 (COPD)). In primary analyses, conditional logistic regression was used to compare
58 the chance of varenicline or NRT exposure in the risk period (90 days prior to the
59 event) with the chance of exposure in an earlier single reference period (91-180 days
60 prior to the event) or multiple 90-day reference periods to increase statistical power.

61 **Findings:** In the primary analyses, findings were inconclusive for the associations
62 between varenicline and the main outcomes using a single reference period, whilst
63 NRT was associated with MI (Odds ratio (OR) 1.40, 95% Confidence interval (CI)
64 1.18 -1.67). Using multiple reference periods, varenicline was associated with an
65 increased risk of self-harm (OR 1.32, 95% CI 1.12- 1.56) and suicide (OR 3.56, 95%
66 CI 1.32- 9.60) but a reduction in all-cause death (OR 0.75, 95% CI 0.61-0.93). NRT

was associated with MI, self-harm, and deaths from MI, COPD and all causes when using multiple reference periods.

Conclusions

The observed associations may not be causal. They may reflect health changes at the time of smoking cessation (nicotine replacement therapy is prescribed for people with cardiac problems) or be associated with quit attempts (exposure to both medicines was associated with self-harm).

88 INTRODUCTION

89 Smoking is the leading preventable cause of morbidity and mortality in many
90 countries. (1, 2) Varenicline, bupropion and nicotine replacement therapy (NRT) are
91 all licensed as smoking cessation medicines in the UK, however, bupropion is much
92 less commonly prescribed than the other medications. (3) Varenicline is the most
93 effective smoking cessation medicine in monotherapy; a network meta-analysis of
94 randomised controlled trials showed that for every 10 smokers who quit with single
95 form nicotine replacement therapy (NRT) or bupropion, about 16 would be expected
96 to quit with varenicline. (4) Consistent findings were reported in a large prospective
97 cohort study which showed that patients prescribed varenicline were more likely to
98 be smoking abstinent than those prescribed NRT, an association which persisted for
99 up to four years. (5) However, varenicline has not been shown to be more effective
100 than combination NRT (for example nicotine patch plus a faster acting form of NRT
101 such as nasal spray, gum or inhalator). (4)

102

103 Concerns about the cardiovascular and neuropsychiatric safety of varenicline led
104 regulatory agencies to issue safety warnings about varenicline's possible adverse
105 effects. (6, 7) From 2009 to 2016, the US Food and Drug Administration (FDA)
106 required that varenicline carry a Black Box warning on its product labelling; this is the
107 agency's strongest safety warning. (6) Although the Black Box warning was removed
108 by the FDA in December 2016, (8) concerns about varenicline persist among some.
109 Coroners have linked varenicline to several suicides in Australia; the FDA's decision
110 to downgrade the safety warning has also been criticised. (9) Concerns have also
111 been raised previously about the relationship between NRT and serious

cardiovascular adverse events in older studies (10, 11) These findings have not been supported by a recent Cochrane review, which found little evidence that NRT increased the risk of MI, although it increased the odds of chest pains and palpitations relative to control. (12)

Various study designs with differing strengths and limitations (13) have been used to investigate these safety issues, including case reports, observational cohort studies and meta-analyses. Whereas studies using data from spontaneous reporting systems have reported an increase in psychiatric adverse effects such as suicide with varenicline use (14), large observational studies, randomised controlled trials (RCTs), meta-analyses and network meta-analyses of RCTs have not supported these findings. (4, 15-24) Additionally, large meta-analyses have provided conflicting evidence regarding whether patients prescribed varenicline are at increased risk of adverse cardiovascular events such as myocardial infarction. (25-28) Similarly, there are conflicting reports regarding the cardiovascular safety of NRT. A meta-analysis by Mills et al. (2010) found that NRT was associated with an elevated risk of chest pain and heart palpitations. (29) However, their more recent network meta-analysis found no evidence that NRT was associated with major adverse cardiovascular events, although an elevated risk was observed for all cardiovascular events, including less serious events such as heart palpitations. (28) A 2018 Cochrane review reported similar findings.(12)

There are concerns about the validity of findings using different study designs. First, although RCTs are considered the gold standard for the evaluation of the intended

effects of medicines, they are rarely powered or designed to detect rare unintended adverse effects. Although one of the key aims of meta-analyses is to combine data from multiple trials and in effect, increase the sample size, the sample size requirements for rare outcomes, e.g. suicide, may still be prohibitively large. (30)

Second, although observational pharmacoepidemiological studies that utilise large primary care databases are more likely to meet the sample size requirements for identifying rare adverse outcomes, they are prone to residual or uncontrolled confounding, in particular confounding by indication. Confounding by indication may arise because individuals who are prescribed a particular medication are likely to differ from those who are not prescribed the drug, because there is a reason or indication for prescribing a drug. (31) For example, the use of smoking cessation medicines may appear to be associated with an increased risk of cardiovascular disease. However, smoking itself is a major risk factor for cardiovascular disease. One approach to overcoming confounding by indication is to compare rates of adverse events in patients prescribed different drugs to treat the same underlying condition (i.e. use of active comparators). (32)

Epidemiological study designs which rely only on cases, known as case-only designs, are increasingly used to avoid pitfalls such as confounding and selection bias which may occur in observational studies with control groups such as cohort and case-control studies.(33) Case only designs (which include the case-crossover method, case time control method and self-controlled case series), may benefit from the elimination of time invariant within-person confounding factors such as socio-economic position and genetic predisposition. Other benefits include having greater

statistical power to detect rare adverse effects and being less costly to carry out compared with conventional observational studies. (33)

In the current study, we estimate the neuropsychiatric and cardiovascular adverse risks of varenicline and NRT in the UK Clinical Practice Research Datalink (CPRD) using a case-crossover study design.

METHODS

Study design and patients

The CPRD is one of the largest primary care databases in the world and contains electronic medical records from >15 million individuals, who are representative of the UK population. (34) In the UK >98% of the population are registered with a general practitioner (GP), who act as gatekeepers of care for the National Health Service. Data from GP consultations as well as information which is fed-back from secondary care referrals are routinely entered onto computers, creating the electronic medical records which the CPRD is comprised of. We used data from the CPRD and linked hospital admissions data from the Hospital Episode Statistics (HES) database and mortality data from the Office of National Statistics (ONS) mortality dataset to conduct a population-based case-crossover study. The case-crossover method is a type of case-only design which is epidemiologically and statistically comparable to matched case-control analyses except the case serves as his/her own control. (35-37) In the simplest design, study participants are compared at two different time points (see Figure 1), the first time point is nearer to the occurrence of the event of interest (referred to as the risk period); the second time point represents a similar

time interval occurring further away from and earlier than the event of interest (referred to as the reference period). Therefore, if a particular treatment were actually associated with a specific outcome, it would be expected that exposure to that treatment would occur more frequently in the risk period than the reference period. The similarity of the case-crossover study to the matched case-control design occurs as only discordant pairs (i.e. those exposed in the risk period but not in the reference period and vice versa) contribute to the statistical analysis. Individuals with concordant matched pairs (i.e. exposed or unexposed to treatment in both time periods) are uninformative.

All hypotheses and analyses (with the exception of the analyses exploring time dependent confounding) were pre-specified in a study protocol which was approved by the Independent Scientific Advisory Committee (ISAC), available from [http://research-information.bristol.ac.uk/en/persons/kyla-h-thomas\(e3917519-6a48-4192-af81-a1199d545b40\)/projects.html](http://research-information.bristol.ac.uk/en/persons/kyla-h-thomas(e3917519-6a48-4192-af81-a1199d545b40)/projects.html) (Accessed 18th March 2020). We used the most recent version of CPRD Gold available at the time (November 2015).

Participants

Patients were included if they were adult smokers from 1st September 2006 (when varenicline was licensed in the UK) onwards to 31st November 2015. Smokers were defined as patients who have a smoking record which indicates current smoker (obtained from the “Additional Clinical Details” file in the CPRD) or Read codes which indicate current smoking after the 1st September 2006. Read codes are a coded thesaurus of clinical terms which are used in electronic health care records in the UK National Health Service. Read code algorithms to define smoking status were

based on those used in a previous study by Szatkowski and McNeill (2013) in The Health Improvement Network (THIN) database, which is similar to the CPRD. (38) The prevalence of current smoking identified from primary care electronic health records has previously been shown to accurately reflect the prevalence reported in national surveys such as the Health Survey for England. (39)

Records from patients classified as 'acceptable' by the CPRD from all up-to-standard practices at least 18 months prior to date of entry of each cohort (1st January 2005) were included. Patient data were defined as "acceptable" by the CPRD if they met minimum quality control standards, for example they had information on sex, date of birth and first registration with no breaks in registration, i.e. a valid GP registration period. Up-to-standard practices included those which reported when their patients first registered with the practice and left the practice, with continuous data reporting in between.

Patients were excluded if they were registered at a GP practice for less than 365 days before the first recorded prescription. We excluded patients prescribed both NRT and varenicline at the same time. In a previous CPRD analysis, this occurred for 0.25% of all prescriptions.(18)

Exposures, outcomes and covariates

Cases included smokers who had experienced one of the following smoking-related outcomes: suicide, non-fatal self-harm (suicide attempt), myocardial infarction (MI)

and death from all causes and the following specific causes- MI, lung cancer and chronic obstructive pulmonary disease (COPD) (the latter were included as major causes of smoking related morbidity and mortality). CPRD Read codes were used to identify self-harm and MI using validated algorithms. (40, 41) HES data were used to identify inpatient hospital admissions for self-harm. Deaths were identified using ONS mortality data. We used linked ONS mortality data to identify MI deaths as previous research has shown that failure to do so may result in biased estimates of MI incidence and outcome. (41) Similarly, CPRD recording of suicide has also been shown to be unreliable although the under-reporting of self-harm is less marked. (40) The following International Classification of Disease Tenth Revision (ICD-10) codes were used for mortality: MI (codes I21-I22), COPD (codes J40-J44), lung cancer (C34, C78, D02.2, D14.3, D38.1), suicide (intentional self-harm, codes X60-X84 and events of undetermined attempt, codes Y10-Y34). In England and Wales, the Office for National Statistics definition of suicides includes deaths given an underlying cause of intentional self-harm in addition to deaths caused by injury or poisoning where the intent was undetermined for those aged 15 and over. This is because most undetermined deaths are likely to be suicides. (42) Inpatient self-harm admissions were identified using the same ICD-10 codes that were used to identify suicide deaths. Only incident events were included in the statistical analysis. Events were assumed to be independent.

Exposure to varenicline or NRT in the CPRD was identified using product codes. A product code is a unique code in the CPRD which is used to identify each specific prescribed medicine selected by a GP for treatment. Product codes are available from the "Therapy file" of the CPRD.

Statistical Analysis

Primary analysis

For the primary analysis, the risk period was defined as 90 days prior to a specific outcome, while the reference period was defined as 91 to 180 days prior to the outcome. A time period of 90 days was chosen as the risk period as the maximum recommended treatment duration for varenicline is 12 weeks (3 months) (<https://bnf.nice.org.uk/drug/varenicline.html> last accessed 18th March 2020). NRT treatment for smoking cessation should also continue for up to 3 months before dose reduction (<https://bnf.nice.org.uk/drug/nicotine.html#indicationsAndDoses> last accessed 18th March 2020). If a study participant was exposed to a particular smoking cessation medicine for at least one day in a given reference period or risk period, the person was considered exposed to that medicine for the entire duration of that period. All analyses were repeated replacing exposure to varenicline with exposure to NRT. NRT was used as a comparator as its mechanism of action is different from varenicline; the association of both medicines with a specific adverse event could therefore imply the event was associated with the timing of smoking cessation instead of a causal effect of the medication. Whilst the case-crossover method deals with time invariant confounding, time varying confounding remains a problem which this approach could potentially address indirectly.

Each study participant formed two halves of a matched pair, comparing exposure to varenicline in the risk period (90 days prior to the outcome event) with exposure to varenicline in a single reference period (90 days before the risk period). Conditional

279 logistic regression was used to calculate odds ratios (ORs) and 95% confidence
280 intervals (CIs) for the discordant matched pairs using the `clogit` command.
281 Analyses were carried out using Stata statistical software version 14MP.

282

283 *Secondary (Sensitivity) analyses*

284 Sensitivity analyses were repeated with 30 days and 180 days prior to the event as
285 the risk period such that the reference periods were 31-60 days prior to the event
286 and 181-360 days prior to the event.

287

288 *Multiple reference periods*

289 Multiple reference periods were used to increase the statistical power of the primary
290 and secondary analyses. This involved using up to a maximum of four reference
291 periods compared to one risk period. For example, in the primary analysis, exposure
292 to varenicline in the risk period (90 days prior to the event) was compared with
293 exposure to varenicline in four 90-day reference periods (i.e. 91-180 days prior to the
294 event, 181-270 days prior to the event, 271-360 days prior to the event and 361-450
295 days prior to the event).

296

297 *Assessment of time dependent confounding*

298 Case-crossover designs assume no unmeasured time dependent confounding. We
299 investigated the possibility of time-dependent confounding in a post-hoc exploratory
300 analysis by estimating the rates of four events: primary care diagnoses and
301 hospitalisation for myocardial infarction and self-harm. Primary care diagnoses were

identified using Read codes in the CPRD. Hospital admissions were identified using the linked hospital admissions dataset using the previously described ICD-10 codes for self-harm and MI. We did this by extracting the weekly number of records indicating each of the four events in the year before and the year after the patients were prescribed any NRT or varenicline prescription. This means there are multiple prescriptions per person and the denominator for this analysis is all NRT or varenicline prescriptions. We set week zero to be the week before the index prescription. We then plotted the event rate by dividing the number of events per week by the number of NRT and varenicline prescriptions.

RESULTS

The baseline characteristics (median age and sex) of participants experiencing events (excluding lung cancer) are shown in Table 1. A flowchart of the number of patients and prescriptions assessed for eligibility and the reasons for exclusion is presented in Figure S1. The number of events for each outcome is shown in Table 2. Lung cancer deaths were excluded from further analysis due to the very small number of events identified. For the majority of patients dying from lung cancer, NRT was not prescribed in either the risk or the reference period; for varenicline this was the case for all lung cancer deaths. NRT was prescribed in the reference period but not the risk period for <5 lung cancer deaths.

Table 2 also shows the association between adverse events in smokers and exposure to varenicline or NRT using 90-day risk, and up to a maximum of four reference periods.

326

327 *Single reference period*

328 For a single 90-day risk period compared to the immediately preceding 90-day
329 reference period, there was inconclusive evidence that varenicline was associated
330 with an increased risk of self-harm (OR 1.07, 95% CI 0.85 -1.35); whilst the risk of
331 suicide was elevated, estimates were imprecise and confidence intervals spanned
332 the null value (OR 3.50, 95% CI 0.73 - 16.85). There was inconclusive evidence of
333 an association between varenicline and self-harm hospital admissions (OR 0.86,
334 95% CI 0.61-1.23), deaths from MI (OR 0.80, 95% CI 0.32-2.03), or COPD (OR 0.92,
335 95% CI 0.53-1.61]). There was a positive association between NRT and MI (OR
336 1.40, 95% CI 1.18-1.67), with inconclusive evidence for other outcomes.

337

338 *Multiple reference periods*

339 When multiple 90-day reference periods were used with a single 90-day risk period
340 to increase statistical power, there was evidence that varenicline was associated
341 with an increased risk of self-harm (OR 1.32, 95% CI 1.12-1.56) and a more than
342 threefold increased risk of suicide (OR 3.56, 95% CI 1.32-9.60). However,
343 varenicline was associated with a reduction in deaths from all causes (OR 0.75, 95%
344 CI 0.61-0.93). NRT was associated with an increased risk of MI (OR 1.54, 95% CI
345 1.36-1.74), self-harm (OR 1.30, 95% CI 1.18-1.44), MI deaths (OR 1.53, 95% CI
346 1.11-2.10), COPD deaths (OR 1.33, 95% CI 1.14-1.56) and all-cause deaths (OR
347 1.28, 95% CI 1.18-1.40). There was inconclusive evidence for an association of NRT
348 with suicide (OR 1.32, 95% CI 0.69-2.53) or self-harm hospital admissions (OR 1.08,
349 95% CI 0.92-1.26).

350

351 *Sensitivity analyses*

352 Secondary (sensitivity) analyses using 30-day and 180-day risk and reference
353 periods are shown in Table S2 and Table S3 respectively and were largely
354 consistent with the findings of the multiple reference period analyses. Using a 30-day
355 risk and reference period, varenicline was associated with a reduced risk of all-cause
356 mortality. NRT was associated with an increased risk of MI. For the 180-day risk and
357 reference periods, varenicline was associated with a reduction in all-cause mortality
358 and COPD deaths and an increased risk of MI, self-harm and inpatient self-harm
359 admissions (using multiple reference periods only). NRT was associated with an
360 increased risk of MI and self-harm. However, NRT was also associated with an
361 increase in MI deaths and all-cause mortality (using multiple reference periods).

362

363 Figure 2 illustrates the rate of primary care diagnoses of and hospital admissions for
364 myocardial infarction in the 52 weeks before and after varenicline and NRT
365 prescriptions. Negative values on the x-axis indicate the weeks before the
366 prescription, positive values indicate the weeks after the prescription. There was a
367 significant increase in the number of diagnoses of MI events in the weeks leading up
368 to a NRT prescription (from 1.2 MI events per 1000 prescriptions 52 weeks before
369 being prescribed NRT to 15.7 events per 1000 prescriptions in the week before
370 being prescribed NRT), followed by a very substantial fall in the number of diagnoses
371 in the weeks following a prescription (from 14.1 events per 1000 in the week of being
372 prescribed NRT to between 1 and 1.5 events per 1000 from the 4th week after being
373 prescribed NRT onwards). The results were similar for the relationship between

hospital admissions for myocardial infarction and NRT prescribing. A similar temporal trend was observed with varenicline prescriptions, although it was much less marked. These findings may be due to non-fatal cardiovascular events or symptoms triggering prescriptions; in our analyses prescription of a smoking cessation product is likely to be affected by within individual time dependent confounding.

Figure 3 illustrates the event rates per 1000 prescriptions for primary care diagnosis and hospital admissions for self-harm. There were much smaller changes in the event rate per 1000 prescriptions for self-harm events compared with MI events over time. Overall, there were small changes in the self-harm event rates before and after NRT prescriptions were issued (event rates were consistently between 0.6 and 0.7 per 1000 prescriptions). However, self-harm events per 1000 prescriptions were markedly lower in the weeks before a varenicline prescription (0.1 to 0.2 events per 1000) compared with the weeks following a varenicline prescription (0.3 to 0.6 events per 1000), showing that varenicline was less likely to be issued if the patient had a recent primary care diagnosis of self-harm, consistent with prescribing guidelines. Similar findings were observed for self-harm hospital admissions.

DISCUSSION

Main findings

In the primary analysis using a single 90-day risk period and reference period we found inconclusive evidence that varenicline increased the risk of any of our outcomes of interest. Although NRT was associated with a 40% (95% CI 18% to

67%) increased risk of MI, there was strong evidence of time dependent confounding suggesting that MI (or heart disease more generally) may lead to the prescription of NRT. Findings were also sensitive to design decisions. When multiple 90-day reference periods were used to increase statistical power, varenicline was associated with a 256% (95% CI 32% to 860%) increased risk of suicide, 32% increased risk of self-harm and a 25% reduction in all-cause mortality. Similarly, NRT was associated with an increased risk of self-harm and deaths from all-causes, MI and COPD. There was inconclusive evidence of an increased risk of self-harm hospital admissions with varenicline or NRT. In the secondary analyses, varenicline was associated with a reduction in all-cause deaths using the shorter 30-day time window for the risk and reference periods and NRT was associated with an increased risk of MI. However, using multiple reference periods and the 180-day risk and reference periods, positive associations were observed for MI and self-harm (varenicline and NRT), self-harm hospital admissions (varenicline only) and deaths from MI and all causes (NRT only).

Strengths and Limitations

The use of data from the CPRD is one of the main strengths of this study. Study participants are likely to be more representative of patients prescribed smoking cessation medicines in the UK compared with the highly selected patients usually included in randomised controlled trials. Second, we used validated code lists and linked datasets to improve the accuracy of detection of our outcomes of interest. (40, 41) Third, we used the case-crossover method to investigate the association of varenicline and NRT with adverse outcomes. Advantages of this study design

include its ability to completely control for between person confounding, minimising within-person time invariant confounding factors (i.e. subject characteristics that remain constant) and statistical efficiency (the use of multiple reference periods for one risk period increases statistical power). (35) Also, as we investigated varenicline as well as NRT, we could assess whether events may have resulted from nicotine withdrawal (e.g. the increased risk of self-harm events observed with both treatments during the 90-day risk and reference period when multiple reference periods were used).

A major study limitation is the observational study design. Therefore, the analysis was still prone to residual time variant confounding, in particular within person confounding by transient factors for example changes in disease severity or comorbid conditions. (37) The result of within person comparisons would also be affected by the choice of comparison periods. We observed strong time-dependent confounding, shown by the temporal patterns in the occurrence of MI and self-harm related events before and after smoking cessation medication prescribing in the exploratory analyses. Patients were more likely to be prescribed NRT following a primary care diagnosis of MI and hospitalisation for MI. Patients prescribed varenicline were less likely to have had a primary care diagnosis or hospital admission for self-harm in the weeks prior to the prescription. This may be because GPs were less likely to prescribe varenicline to patients who have recently self-harmed. Although we observed an association between both varenicline and NRT and self-harm events in our primary analyses using multiple reference periods, we did not find evidence of any associations with self-harm hospitalisations. This may

have been caused by a lack of statistical power as we identified half as many self-harm hospitalisations as self-harm events.

We were unable to perform case time control analyses as stated in our original protocol as we could not obtain a sufficient number of matched controls. This would have allowed statistical adjustments to be made for a common time trend such as a change in the prescribing pattern of the smoking cessation medicines. (37) However, this is unlikely to be an issue in the short time periods utilised in the main analyses. It is important to note that our analyses were also sensitive to some of our design decisions, for example the number of matching periods and the duration of the risk and reference periods. In the primary analysis, the use of multiple reference periods provided a point estimate in a more harmful direction to the result using a single reference period for MI and self-harm hospital admissions in the varenicline group. Additionally, for both varenicline and NRT, increases in the length of the risk and reference periods from 30 days to 180 days resulted in a greater number of positive associations using multiple reference periods. This may be indicative of a temporal bias which was not fully accounted for in the analyses, i.e. with increasing time from the event occurrence, the potential for time dependent confounding increases due to changes in the individual such as changes in health status. This is suggested by the strong temporal pattern of event rates we observed around the time smoking cessation medication was started.

Our analyses were also restricted to products prescribed in primary care (thus excluding patients receiving smoking cessation products in smoking cessation clinics

or buying over the counter NRT from pharmacies). Those who visit a healthcare professional for prescribed medications are likely to be sicker and to be less affluent or of a lower socioeconomic position compared to those buying over the counter medicines. (43) Therefore, the analyses may not be generalisable to the wider population of people taking smoking cessation medicines including those obtained over the counter without a prescription. Additionally, being prescribed medication does not mean that the patient actually took the medication. We had no information on treatment compliance or adherence but problems with either would tend to bias results towards a null effect.

Comparison with other case only studies

Three recent studies have used within person designs to investigate the neuropsychiatric and cardiovascular safety of varenicline. (44-46) Monarrez- Espino et al. (2018) carried out a case-crossover study using data from Swedish health and administrative registers. (44) They reported on four different hazard (risk) periods, including a hazard period of 1-84 days, which approximates to our main analyses using a 90-day risk and reference period. There was inconclusive evidence that varenicline was associated with MI (OR 0.98, 95% CI 0.80-1.22), suicide (OR 0.58, 95% CI 0.32-1.06) or suicide attempt (OR 0.82, 95% CI 0.63-1.07). However, varenicline was associated with a reduction in the outcome which combined suicide and suicide attempt (OR 0.77, 95% CI 0.60-0.98). These findings are not consistent with our study, possibly due to differences in the study populations or differences in prescribing behaviour for smoking cessation in Sweden compared with the UK, leading to different temporally associated changes in risk. Gershon et al. (2018) used

a self-controlled risk interval study design to investigate neuropsychiatric and cardiovascular hospitalisations with varenicline. (45) Similar to the case-crossover study, each patient acts as his/her own control, minimising within-person time invariant confounding. However, it differs from the case-crossover study design as for patients exposed to a particular treatment, it examines the risk of the outcome of interest in a specified period closest to the exposure (risk period) with a remaining observation period (control period). For new users of varenicline, the authors found a 34% higher incidence of cardiovascular events in the 12-week risk period compared with the control interval (relative incidence 1.34, 95% CI 1.25-1.44). An increase in the incidence of neuropsychiatric events was also observed for varenicline (relative incidence 1.06, 95% CI 1.00-1.13). This finding is similar to our finding for the association of varenicline and self-harm in the main analyses (OR 1.07, 95% CI 0.85-1.35). The differences in the results for cardiovascular outcomes may be due to the differences in estimation of the risk periods and population size. The authors did not examine outcomes in relation to NRT.

Molero et al. (2015) used a within-person comparison cohort design to examine associations between varenicline and a range of outcomes including new psychiatric conditions and suicidal behaviour.(46) Although varenicline was not shown to be associated with suicidal behaviour (hazard ratio 1.00, 95% CI 0.72-1.37), it was associated with an increase in the risk of anxiety conditions (hazard ratio 1.27, 95% CI 1.06-1.51) and mood conditions (hazard ratio 1.28, 95% CI 1.07-1.52). Suicidal behaviour was defined as emergency inpatient or outpatient hospital visits or death due to intentional self-harm and differed from our analyses as they did not include ICD codes for undetermined events or deaths.

One study examined the use of NRT and the risk of acute MI, stroke and death in the The Health Improvement Network (THIN), using the self-controlled case series method. (47) The incidence of MI increased in the 56 days prior to the first prescription of NRT (incidence ratio 5.55, 95% CI 4.42 to 6.98) although it was not increased in the 56 days following the first NRT prescription (incidence ratio 1.27, 95% CI 0.82 to 1.97). However, there was an increased risk of MI in the first 14 days following NRT prescription (incidence ratio 2.39, 95% CI 1.28 to 4.48) which is consistent with our findings.

Comparison with other study designs

With respect to neuropsychiatric outcomes, our results from the primary analyses using a single 90-day risk period and multiple 90-day reference periods are consistent with prescription event monitoring studies and studies using adverse event reporting databases, which have reported an increased risk of reported suicidal behaviour for varenicline compared with NRT.(14, 48-51) However, previous studies which included comparison groups (i.e. RCTs, meta-analyses of RCTs and other observational study designs) have reported inconclusive findings as to whether varenicline is associated with an increased risk of suicide, suicide attempt or other mental disorders (depression, neurotic disorders or prescriptions for anti-depressants). (15-22) This could partly be because most RCTs and meta-analyses of RCTs would not have sufficient statistical power to detect an effect of prescribing varenicline on such a rare outcome. (19, 21) For example, the large EAGLES study found no significant increase in neuropsychiatric events with varenicline compared to placebo or NRT. (21) The study had a sample size of 8144 participants across four

treatment groups; it was statistically powered to detect an adverse event which occurred in at least 4% of patients in any treatment group (a moderate effect size). However, a sample size of 21,584 would be needed for a clinical trial to detect the more than threefold increase we observed for suicide in this study, based on a suicide incidence rate of 9.2 per 100,000 at 80% power and 5% significance. Previous meta-analyses of neuropsychiatric events have included <12,000 participants and reported very few suicides; therefore the lack of statistical power to detect an effect would also be an issue in these studies. (19, 23) Previous observational cohort studies which found inconclusive evidence between smoking cessation medicines and neuropsychiatric outcomes or a negative association were also likely to be impacted by residual confounding (those prescribed varenicline were healthier than those prescribed NRT) and/or the very limited numbers of suicides identified (<10). (15, 18, 20, 24) Our study found an association between self-harm and being prescribed NRT or varenicline which may be explained by an association between quit attempts and self-harm. Although nicotine withdrawal is known to be associated with mood changes (52), evidence showing a clear association with self-harm is lacking.

Our findings for all-cause mortality suggest caution is needed when interpreting results. Varenicline was associated with a reduction in all-cause mortality, consistent with findings using conventional methods of analyses (multivariable regression and propensity score matching) from previous UK primary care observational studies using the CPRD and the Q Research database. (18, 20) The protective effect of varenicline on all-cause mortality was not driven solely by a reduction in COPD or MI deaths. However, we were unable to identify the specific causes behind this

protective effect as our CPRD extract did not include causes of death we had not prespecified in our protocol. Conversely, we found that NRT was associated with higher all-cause mortality in our primary analyses using a single 90-day risk period and multiple 90-day reference periods. However, it is possible that all of the analyses may have been affected by time dependent residual confounding. Additionally, previous studies have shown that people prescribed varenicline are likely to be healthier than those prescribed NRT(15, 18, 20) .

Findings regarding the cardiovascular safety of varenicline are also conflicting. In this study, varenicline was only associated with an increased risk of MI events for the 180-day risk and reference period using multiple reference periods. Although a 19% increased risk of MI events was observed in the 90-day risk and reference period, the 95% CI included the null. Previous studies (including the EAGLES study and its nontreatment extension, (53) meta-analyses of RCTs (26, 28) and an observational study (20)) found no increase in cardiovascular events with varenicline or NRT. However, a systematic review of varenicline versus placebo found evidence of an increased risk. (25) The Mills et al. (2014) network meta-analysis also found an elevated risk of cardiovascular events associated with NRT, mostly due to less serious events, but was underpowered to assess the risk of serious events. (28) A recent cohort study using the CPRD also found an increase in cardiovascular events by 52 weeks for patients prescribed NRT compared with those receiving smoking cessation advice only. (54) These findings are consistent with our study. This association may be due to smokers who experience worsening of symptoms such as chest pain being more likely to seek help from their GPs to quit smoking (as shown by Figure 2).

593

594 **Conclusions**

595 In this study, we used a case-crossover study design to investigate the risk of
596 neuropsychiatric and cardiovascular outcomes associated with varenicline and NRT
597 in a real-world setting. For primary analyses using a 90-day risk period and multiple
598 reference periods, we observed associations between varenicline and suicide and
599 self-harm as well as associations between NRT and self-harm, MI, MI deaths and all-
600 cause mortality. However, these temporal associations may not be causal, as we
601 also found strong evidence of time dependent confounding, particularly for our NRT
602 analyses where those experiencing MI were likely to be prescribed NRT in the week
603 before the event. The evidence was much less marked for varenicline. The
604 association of both varenicline and NRT with self-harm in our study may reflect an
605 association between self-harm and quit attempts, rather than a causal association
606 with the smoking cessation medications. Additionally, associations such as a
607 reduction in all-cause mortality with varenicline and an increased risk of COPD
608 deaths with NRT may be explained by differences in GP prescribing behaviour
609 (healthier patients are prescribed varenicline) or changes in health status (for
610 example COPD exacerbation triggering NRT prescribing). Further evidence will be
611 provided when the results of the largest network meta-analysis of smoking cessation
612 medicines and e-cigarettes are reported. (55) The study will report on smoking
613 abstinence in addition to safety outcomes including serious adverse events, major
614 adverse neuropsychiatric events (including suicide and self-harm) and major adverse
615 cardiovascular events. Further research can aim to replicate our study using similar
616 datasets, for example Scandinavian record linkage studies and large North American
617 health care databases. Additionally, mendelian randomisation and genetic

618 correlation studies may provide further information on associations with self-harm.
619 What is clear, is that regardless of cause, people attempting to stop smoking with
620 smoking cessation therapies appear to have a higher risk of neuropsychiatric and
621 cardiorespiratory events which may be due to time dependent confounding (people
622 who are sicker seeking treatment), or theoretically an effect of taking smoking
623 cessation therapy. More research is needed to elucidate these relationships.

624

625 **Author contributions:** KHT, ND and ID originally conceived the study. KHT drafted
626 its funding application with support from DG. KHT and ND wrote the statistical script
627 and analysed the data. KHT wrote the initial draft of the manuscript. All authors
628 contributed to the interpretation of the results, revising the manuscript and gave final
629 approval of the version to be published. KHT and ND are the study guarantors, had
630 full access to all of the data in the study and take responsibility for the integrity of the
631 data and the accuracy of the data analysis.

632

633 **Acknowledgements and Funding:** This project was supported by the Academy of
634 Medical Sciences Starter Grant for Clinical Lecturers Scheme, which is supported by
635 the Wellcome Trust, the Medical Research Council, the British Heart Foundation,
636 Versus Arthritis, Prostate Cancer UK and the Royal College of Physicians. The
637 scheme provided resources to enable access to the CPRD. The funders had no role
638 in the study design, data collection and analysis, decision to publish, or preparation
639 of the manuscript. The corresponding author had full access to the data used in this
640 study and had final responsibility for the decision to submit for peer reviewed
641 publication. The views expressed in this publication are those of the authors and are

not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

KHT is currently funded by a National Institute for Health Research Postdoctoral Fellowship (PDF-2017-10-068). Part of this work was undertaken while KHT was funded by a clinical lectureship from the National Institute for Health Research. NMD is supported by a Norwegian Research Council Grant Number 295989. GT is funded by a Cancer Research UK Population Researcher Postdoctoral Fellowship award (reference:C56067/A21330). IJD is funded by an unrestricted grant from GlaxoSmithKline. RMM, DG and AT are supported by the NIHR Bristol Biomedical Research Centre, a partnership between the University Hospitals Bristol NHS Foundation Trust and University of Bristol. RMM is also supported by a Cancer Research UK programme grant (C18281/A19169). AT, GT and ND have received a Global Research Award for Nicotine Dependence (GRAND), an independently reviewed, competitive grants programme supported by Pfizer, to the University of Bristol.

Data Statement: Data used in the project are available from a third party, the Clinical Practice Research Datalink (contact info enquiries@cprd.com). The data can be accessed by submitting an application to the Independent Scientific Advisory Committee (<https://cprd.com/Data-access>). Ethical Approval was not required for this project.

666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685

For Review Only

REFERENCES

1. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. *BMJ*. 2000;321(7257):323-9.
2. Jha P, Peto R. Global Effects of Smoking, of Quitting, and of Taxing Tobacco. *N Engl J Med*. 2014;370(1):60-8.
3. Health and Social Care Information Centre. Statistics on Smoking: England 2016. 2016.
4. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev*. 2013;5.
5. Taylor GMJ, Taylor AE, Thomas KH, Jones T, Martin RM, Munafo MR, et al. The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records. *Int J Epidemiol*. 2017;46(6):1948-57.
6. US Food and Drug Administration. Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin and generics). FDA Drug Safety Newsletter [Internet]. 2009 18th March 2020; 2(1). Available from: <https://wayback.archive-it.org/7993/20170112005513/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm169988.htm>.
7. US Food and Drug Administration. FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events. Drug Safety and Availability [Internet]. 2012 Accessed 18th March 2020. Available

- 710 from: [https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-chantix-varenicline-and-risk-cardiovascular)
711 [communication-safety-review-update-chantix-varenicline-and-risk-cardiovascular](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-chantix-varenicline-and-risk-cardiovascular).
- 712 8. US Food and Drug Administration. FDA Drug Safety Communication: FDA
713 revises description of mental health side effects of the stop-smoking medicines
714 Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. Drug
715 Safety and Availability [Internet]. 2016 Accessed 18th March 2020. Available from:
716 [https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking)
717 [communication-fda-revises-description-mental-health-side-effects-stop-smoking](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking).
- 718 9. MacKenzie R. Champix's effectiveness is questionable and safety record is
719 concerning. The Conversation [Internet]. 2017 Accessed 18th March 2020. Available
720 from: [https://theconversation.com/weekly-dose-champixs-effectiveness-is-](https://theconversation.com/weekly-dose-champixs-effectiveness-is-questionable-and-safety-record-is-concerning-85259)
721 [questionable-and-safety-record-is-concerning-85259](https://theconversation.com/weekly-dose-champixs-effectiveness-is-questionable-and-safety-record-is-concerning-85259).
- 722 10. Dacosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M, et al.
723 Myocardial infarction and nicotine patch: a contributing or causative factor? Eur
724 Heart J. 1993;14(12):1709-11.
- 725 11. Najem B, Houssiere A, Pathak A, Janssen C, Lemogoum D, Xhaet O, et al.
726 Acute cardiovascular and sympathetic effects of nicotine replacement therapy.
727 Hypertension. 2006;47(6):1162-7.
- 728 12. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine
729 replacement therapy versus control for smoking cessation. Cochrane Database of
730 Systematic Reviews. 2018(5).
- 731 13. Strom BL. Study designs available for Pharmacoepidemiology studies. In:
732 Strom BL, Kimmel SE, editors. Textbook of pharmacoepidemiology. Chichester,
733 West Sussex, England: John Wiley and Sons; 2006. p. 13-24.

- 734 14. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal
735 Behavior and Depression in Smoking Cessation Treatments. *Plos One*.
736 2011;6(11):e27016.
- 737 15. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal
738 behaviour: a cohort study based on data from the General Practice Research
739 Database. *BMJ*. 2009;339.
- 740 16. Meyer TE, Taylor LG, Xie S, Graham DJ, Mosholder AD, Williams JR, et al.
741 Neuropsychiatric events in varenicline and nicotine replacement patch users in the
742 Military Health System. *Addiction*. 2013;108(1):203-10.
- 743 17. Gibbons RD, Mann JJ. Varenicline, Smoking Cessation, and Neuropsychiatric
744 Adverse Events. *Am J Psychiatry*. 2013.
- 745 18. Thomas KH, Martin RM, Davies N, Metcalfe C, Windmeijer F, Gunnell D.
746 Smoking cessation treatment and the risk of depression, suicide and self-harm in the
747 Clinical Practice Research Datalink: prospective cohort study *BMJ*. 2013;347:f5704.
- 748 19. Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of
749 neuropsychiatric adverse events associated with varenicline: systematic review and
750 meta-analysis. *BMJ*. 2015;350:h1109.
- 751 20. Kotz D, Viechtbauer W, Simpson C, van Schayck OCP, West R, Sheikh A.
752 Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort
753 study. *The Lancet Respiratory Medicine*. 2015;3(10):761-8.
- 754 21. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et
755 al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch
756 in smokers with and without psychiatric disorders (EAGLES): a double-blind,
757 randomised, placebo-controlled clinical trial. *Lancet*. 2016;387(10037):2507-20.

- 758 22. Taylor G, Davies N, Thomas K, Rai D, Jones T, Windmeijer F, et al.
759 Prescribing prevalence, long-term effectiveness, and mental health safety of
760 varenicline and nicotine replacement therapy in patients with mental disorders: A
761 prospective cohort study of electronic medical records. *Nicotine & tobacco research* :
762 official journal of the Society for Research on Nicotine and Tobacco. 2019;in press.
- 763 23. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T.
764 Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst*
765 *Rev.* 2016(5):Cd006103.
- 766 24. Carney G, Bassett K, Maclure M, Taylor S, Dormuth CR. Cardiovascular and
767 neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed
768 adults: a retrospective cohort study. *Addiction.* 2020;115(8):1534-46.
- 769 25. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse
770 cardiovascular events associated with varenicline: a systematic review and meta-
771 analysis. *Canadian Medical Association Journal.* 2011;183(12):1359-66.
- 772 26. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events
773 associated with varenicline use for tobacco cessation: systematic review and meta-
774 analysis. *BMJ.* 2012;344.
- 775 27. Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and
776 Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of
777 Randomized Controlled Trials. *Journal of the American Heart Association.* 2016;5(2).
- 778 28. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events
779 associated with smoking cessation pharmacotherapies: a network meta-analysis.
780 *Circulation.* 2014;129(1):28-41.
- 781 29. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated
782 with nicotine replacement therapy (NRT) for smoking cessation. A systematic review

- 783 and meta-analysis of one hundred and twenty studies involving 177,390 individuals.
784 Tob Induc Dis. 2010;8:8.
- 785 30. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors
786 (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo
787 controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ.
788 2005;330:385-8.
- 789 31. Walker AM. Confounding by indication. Epidemiology. 1996;7(4):335-6.
- 790 32. Norgaard M, Ehrenstein V, Vandenbroucke JP. Confounding in observational
791 studies based on large health care databases: problems and potential solutions - a
792 primer for the clinician. Clin Epidemiol. 2017;9:185-93.
- 793 33. Nordmann S, Biard L, Ravaud P, Esposito-Farèse M, Tubach F. Case-Only
794 Designs in Pharmacoepidemiology: A Systematic Review. Plos One.
795 2012;7(11):e49444.
- 796 34. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al.
797 Data Resource Profile: Clinical Practice Research Datalink (CPRD). IntJ Epidemiol.
798 2015;44(3):827-36.
- 799 35. Maclure M. The Case-Crossover Design: A Method for Studying Transient
800 Effects on the Risk of Acute Events. American Journal of Epidemiology.
801 1991;133(2):144-53.
- 802 36. Delaney JA, Suissa S. The case-crossover study design in
803 pharmacoepidemiology. Statistical Methods in Medical Research. 2009;18(1):53-65.
- 804 37. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control
805 designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol
806 Drug Saf. 1997;6 Suppl 3:S51-9.

- 807 38. Szatkowski L, McNeill A. The delivery of smoking cessation interventions to
808 primary care patients with mental health problems. *Addiction*. 2013;108(8):1487-94.
- 809 39. Booth HP, Prevost AT, Gulliford MC. Validity of smoking prevalence estimates
810 from primary care electronic health records compared with national population
811 survey data for England, 2007 to 2011. *Pharmacoepidemiol Drug Saf*. 2013;22.
- 812 40. Thomas KH, Davies N, Metcalfe C, Windmeijer F, Martin RM, Gunnell D.
813 Validation of Suicide and Self-harm records in the Clinical Practice Research
814 Datalink. *Br J Clin Pharmacol*. 2013;76(1):145-57.
- 815 41. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, et al.
816 Completeness and diagnostic validity of recording acute myocardial infarction events
817 in primary care, hospital care, disease registry, and national mortality records: cohort
818 study. *BMJ*. 2013;346:f2350.
- 819 42. Gunnell D, Bennewith O, Simkin S, Cooper J, Klineberg E, Rodway C, et al.
820 Time trends in coroners' use of different verdicts for possible suicides and their
821 impact on officially reported incidence of suicide in England: 1990-2005.
822 *Psychological Medicine*. 2013;43(7):1415-22.
- 823 43. Johnson M, Anderson P, Lockhart I. General practitioner prescribing of single
824 and combination nicotine replacement therapy in the UK: a retrospective database
825 study. *Bmc Fam Pract*. 2014;15:47.
- 826 44. Monarrez-Espino J, Galanti MR, Hansson J, Janszky I, Soderberg-Lofdal K,
827 Moller J. Treatment With Bupropion and Varenicline for Smoking Cessation and the
828 Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study.
829 *Nicotine Tob Res*. 2018;20(5):606-13.

- 830 45. Gershon AS, Campitelli MA, Hawken S, Victor C, Sproule BA, Kurdyak P, et
831 al. Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking
832 Cessation. *Am J Respir Crit Care Med*. 2018;197(7):913-22.
- 833 46. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and
834 risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport
835 accidents and offences: population based cohort study. *BMJ*. 2015;350:h2388.
- 836 47. Hubbard R, Lewis S, Smith C, Godfrey C, Smeeth L, Farrington P, et al. Use
837 of nicotine replacement therapy and the risk of acute myocardial infarction, stroke,
838 and death. *Tob Control*. 2005;14(6):416-21.
- 839 48. Harrison-Woolrych M, Ashton J. Psychiatric Adverse Events Associated with
840 Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand.
841 *Drug Saf*. 2011;34(9):763-72
- 842 49. Kasliwal R, Wilton LV, Shakir SAW. Safety and Drug Utilization Profile of
843 Varenicline as Used in General Practice in England: Interim Results from a
844 Prescription-Event Monitoring Study. *Drug Saf*. 2009;32(6):499-507
- 845 50. Campbell AR, Anderson KD. Mental health stability in veterans with
846 posttraumatic stress disorder receiving varenicline. *Am J Health Syst Pharm*.
847 2010;67(21):1832-7.
- 848 51. Thomas KH, Martin RM, Potokar J, Pirmohamed M, Gunnell D. Reporting of
849 drug induced depression and fatal and non-fatal suicidal behaviour in the UK from
850 1998 to 2011. *BMC Pharmacol Toxicol*. 2014;15:54.
- 851 52. Hughes JR. Effects of Abstinence From Tobacco: Valid Symptoms and Time
852 Course. *Nicotine & tobacco research : official journal of the Society for Research on*
853 *Nicotine and Tobacco*. 2007;9(3):315-27.

- 854 53. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al.
855 Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A
856 Randomized Clinical Trial. *JAMA Intern Med.* 2018;178(5):622-31.
- 857 54. Dollerup J, Vestbo J, Murray-Thomas T, Kaplan A, Martin RJ, Pizzichini E, et
858 al. Cardiovascular risks in smokers treated with nicotine replacement therapy: a
859 historical cohort study. *Clin Epidemiol.* 2017;9:231-43.
- 860 55. Thomas KH, Caldwell D, Dalili MN, Gunnell D, Munafo MR, Stevenson M, et
861 al. How do smoking cessation medicines compare with respect to their
862 neuropsychiatric safety? A protocol for a systematic review, network meta-analysis
863 and cost-effectiveness analysis. *BMJ Open.* 2017;7(6):e015414.

864

865

866

867

868

869

870


871

872

873


874

Figure 1 Case-crossover analysis illustrating risk and reference periods and exposure to treatment



Legend: 'X' represents exposure to a particular treatment. Concordance occurs where there is exposure to treatment in both periods or exposure in neither periods. Discordance occurs where there is exposure to treatment in the risk period but not the reference period or exposure in the reference period but not the risk period.

894 **Figure 2- Rate of MI events and hospital admissions per 1000 prescriptions in**
895 **the weeks before and after being prescribed varenicline or NRT**



896

897

898 **Figure 3- Rate of self-harm events and hospital admissions per 1000**
899 **prescriptions in the weeks before and after being prescribed varenicline or**
900 **NRT**




Table 1. Baseline characteristics of the cases included in the analyses (people experiencing events).

Characteristic	Outcomes under investigation						
	Myocardial infarction events	Myocardial infarction deaths	Self-Harm events	Self-Harm Hospital Admissions	Suicide deaths	COPD deaths	All deaths
All	19,664	3,461	25,455	12,584	679	8,730	51,786
% female	30.9	36.4	55.5	54.7	25	44.8	44.2
Median age in years	65	75	36	37	45	77	75

Table 2. Odds ratios and 95% confidence intervals of exposure to Varenicline and NRT using 90-day risk and reference periods for specific adverse events.

Adverse event	Number of events	Number Exposed risk period but Not exposed ref period	Number Not exposed risk period but exposed ref period	OR (95% CI) 1:1 matching	OR (95% CI) 1:4* matching
<i>Varenicline</i>					
MI events	19,664	96	113	0.85 (0.65-1.12)	1.19 (0.98-1.45)
Self-Harm events	25,455	151	141	1.07 (0.85-1.35)	1.32 (1.12-1.56)
Self-Harm hospital admissions	12,584	57	66	0.86 (0.61-1.23)	1.08 (0.83-1.42)
MI deaths	3,461	8	10	0.80 (0.32-2.03)	0.82 (0.44-1.66)
Suicide deaths	679	7	2	3.50 (0.73-16.85)	3.56 (1.32-9.60)
COPD deaths	8,730	24	26	0.92 (0.53-1.61)	0.92 (0.64-1.37)
All cause deaths	51,786	84	105	0.80 (0.60-1.07)	0.75 (0.61-0.93)
<i>NRT</i>					
MI events	19,664	303	216	1.40 (1.18-1.67)	1.54 (1.36-1.74)
Self-harm events	25,455	433	414	1.04 (0.91-1.20)	1.30 (1.18-1.44)
Self-harm hospital admissions	12,584	155	183	0.85 (0.68-1.05)	1.08 (0.92-1.26)
MI deaths	3,461	36	32	1.13 (0.70-1.81)	1.53 (1.11-2.10)
Suicide deaths	679	11	7	1.57 (0.61-4.05)	1.32 (0.69-2.53)
COPD deaths	8,730	155	146	1.06 (0.85-1.34)	1.33 (1.14-1.56)
All cause deaths	51,786	556	533	1.04 (0.93-1.18)	1.28 (1.18-1.40)

*Matching on a maximum of four 90-day reference (ref) periods to increase statistical power. Non-null findings are bolded.

For Review Only